{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:58:47Z","timestamp":1784350727807,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"DOI":"10.1038\/s44276-024-00076-4","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T08:04:00Z","timestamp":1720685040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ropeginterferon alfa-2b shows anti-polycythaemia vera activity without causing clinically significant anaemia"],"prefix":"10.1038","volume":"2","author":[{"given":"Keita","family":"Kirito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Suo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfeng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoxiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleh","family":"Zagrijtschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"76_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00277-015-2357-4","volume":"94","author":"M Griesshammer","year":"2015","unstructured":"Griesshammer M, Gisslinger H, Mesa R. Current and future treatment options for polycythemia vera. Ann Hematol. 2015;94:901\u201310.","journal-title":"Ann Hematol"},{"key":"76_CR2","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1182\/blood.2022017697","volume":"141","author":"AR Moliterno","year":"2023","unstructured":"Moliterno AR, Kaizer H, Reeves BN. JAK2V617F allele burden in polycythemia vera: burden of proof. Blood. 2023;141:1934\u201342.","journal-title":"Blood"},{"key":"76_CR3","unstructured":"NCCN. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: myeloproliferative neoplasms. version 1. 2024. www.nccn.org. Assessed 30 January 2024."},{"key":"76_CR4","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1111\/bcp.15176","volume":"88","author":"YW Huang","year":"2022","unstructured":"Huang YW, Qin A, Fang J, Wang TF, Tsai CW, Lin KC, et al. Novel long-acting ropeginterferon alfa-2b: pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial. Br J Clin Pharm. 2022;88:2396\u2013407.","journal-title":"Br J Clin Pharm"},{"key":"76_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40261-021-01026-5","volume":"41","author":"N Miyachi","year":"2021","unstructured":"Miyachi N, Zagrijtschuk O, Kang L, Yonezu K, Qin A. Pharmacokinetics and pharmacodynamics of ropeginterferon alfa-2b in healthy Japanese and Caucasian subjects after single subcutaneous administration. Clin Drug Investig. 2021;41:391\u2013404.","journal-title":"Clin Drug Investig"},{"key":"76_CR6","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomized, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196\u2013208.","journal-title":"Lancet Haematol"},{"key":"76_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12185-022-03341-9","volume":"116","author":"Y Edahiro","year":"2022","unstructured":"Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, et al. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol. 2022;116:215\u201327.","journal-title":"Int J Hematol"},{"key":"76_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40164-023-00415-0","volume":"12","author":"J Jin","year":"2023","unstructured":"Jin J, Zhang L, Qin A, Wu D, Shao Z, Bai J, et al. A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera. Exp Hematol Oncol. 2023;12:55.","journal-title":"Exp Hematol Oncol"},{"key":"76_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.14740\/jh1245","volume":"13","author":"S Suo","year":"2024","unstructured":"Suo S, Fu R, Qin A, Shao Z, Bai J, Chen S, et al. Effective management of polycythemia vera with ropeginterferon alfa-2b. J Hematol. 2024;13:12\u201322.","journal-title":"J Hematol"},{"key":"76_CR10","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","volume":"8","author":"T Barbui","year":"2021","unstructured":"Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8:e175\u2013e184.","journal-title":"Lancet Haematol"},{"key":"76_CR11","unstructured":"Ruxolitinib US label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/202192s028lbl.pdf (accessed May 20, 2024)."},{"key":"76_CR12","doi-asserted-by":"publisher","first-page":"2204621","DOI":"10.1080\/16078454.2023.2204621","volume":"28","author":"RMF Randrianarisoa","year":"2023","unstructured":"Randrianarisoa RMF, Ramanandafy H, Mania A, Monjanel H, Trouillier S. Prevalence and diagnostic performance of iron deficiency in polycythemia. Hematol. 2023;28:2204621.","journal-title":"Hematol"},{"key":"76_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1365-2141.1992.tb02999.x","volume":"81","author":"G Birgeg\u00e5rd","year":"1992","unstructured":"Birgeg\u00e5rd G, Wide L. Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment. Br J Haematol. 1992;81:603\u20136.","journal-title":"Br J Haematol"},{"key":"76_CR14","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.2021012743","volume":"139","author":"J Mascarenhas","year":"2022","unstructured":"Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, et al. A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022;139:2931\u201341.","journal-title":"Blood"},{"key":"76_CR15","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426\u201335.","journal-title":"N Engl J Med"},{"key":"76_CR16","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/MBC.0000000000000249","volume":"26","author":"SH Hung","year":"2015","unstructured":"Hung SH, Lin HC, Chung SD. Association between venous thromboembolism and iron-deficiency anemia. Blood Coagul Fibrinolysis. 2015;26:368\u201372.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"76_CR17","first-page":"261","volume":"90","author":"ML Randi","year":"2005","unstructured":"Randi ML, Ruzzon E, Luzzatto G, Tezza F, Girolami A, Fabris F. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica. 2005;90:261\u20132.","journal-title":"Haematologica"},{"key":"76_CR18","first-page":"EVIDoa2200335","volume":"2","author":"T Barbui","year":"2023","unstructured":"Barbui T, Vannucchi AM, De Stefano V, Carobbio A, Ghirardi A, Carioli G, et al. Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera. NEJM. 2023;2:EVIDoa2200335.","journal-title":"NEJM"},{"key":"76_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1173467","volume":"13","author":"A Qin","year":"2023","unstructured":"Qin A. An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1. Front Oncol. 2023;13:1173467.","journal-title":"Front Oncol"}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-024-00076-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-024-00076-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-024-00076-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T08:10:17Z","timestamp":1720685417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-024-00076-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["76"],"URL":"https:\/\/doi.org\/10.1038\/s44276-024-00076-4","relation":{},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]},"assertion":[{"value":"29 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K Kirito received honoraria for lectures, presentations, speaking engagements, manuscript writing, or educational events from AbbVie G.K., Novartis Pharma K.K., PharmaEssentia Japan K.K., Sanofi K.K., and Takeda Pharmaceutical Co., Ltd. A Qin is the chief medical officer of PharmaEssentia Corporation. K Shimoda is a consultant for Sierra Oncology, Inc. and reports research funding from AbbVie G.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Otsuka Pharmaceutical Co., Ltd., PharmaEssentia Japan K.K., Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd. and honoraria from Takeda Pharmaceutical Co., Ltd., and Novartis Pharma K.K.; and is a member of an advisory committee for AbbVie G.K. N Komatsu is a board member of and received funding for medical writing and article processing charges from PharmaEssentia Japan K.K. and received research funding from Meiji Seika Pharma Co., Ltd. and consulting fees from Torii Pharmaceutical Co., Ltd. T Sato is employed by PharmaEssentia Japan K.K. O Zagrijtschuk is employed by PharmaEssentia USA. D Wu is employed by Biotech (Beijing) Ltd. S Suo, R Fu, and J Jin have no conflict of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Both A19-201 and A20-202 were conducted in compliance with the ethical standards of the responsible institution regarding human subjects. The studies were approved by the ethics committee or IRB of the participating institutions and followed the principles of the Declaration of Helsinki for all human experimental investigations. The institutions are Juntendo University School of Medicine Hospital; Mie University Hospital; Tokyo Medical University Hospital; Ehime University Graduate School of Medicine Hospital; Osaka University Graduate School of Medicine Hospital; Keio University School of Medicine Hospital; NTT Medical Centre Tokyo University of Yamanashi Hospital; The First Affiliated Hospital, Zhejiang University School of Medicine; Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; The Second Hospital of Tianjin Medical University; The First Affiliated Hospital of Soochow University; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital; Nanfang Hospital of Southern Medical University; Ruijin Hospital, Shanghai Jiaotong University School of Medicine; Zhongnan Hospital, Wuhan University; Shenzhen Second People\u2019s Hospital; The First Affiliated Hospital of Chongqing Medical University; Huashan Hospital of Fudan University; The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all participating patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"51"}}